1. EYLEA and Dupixent sales drive company revenue to new records; 2. R&D expenses are projected to reach $5 billion, but the business remains highly profitable; 3. Regeneron is liquid and solvent, but growth rates are falling; 4. The company's value appears overvalued according to quantitative analysis; 5. The author is holding the position for long-term growth and benefits.

1. Amgen's stock is currently fairly valued at 16.6x next year's earnings, supported by strong existing revenue growth and a diversified product portfolio. 2. New products like Blincyto, Tezspire, and Tepezza are driving significant revenue growth, validating recent share price appreciation. 3. MariTide, Amgen's GLP-1 candidate, offers potential upside due to its long-lasting effects and less frequent dosing, potentially addressing current market shortages.

1. A new research project, RauPE, aims to automate the production of stem cell therapies, making them accessible to a larger number of patients. 2. The project involves developing a robust automated expansion platform based on BioThrust's membrane stirrer bioreactor. 3. The goal is to create a scalable process for producing ciMSC-EV preparations that meets the certification requirements for medical products.